XML 53 R43.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2023
Stockholders' Equity  
Schedule of key assumptions to determine fair value of options

Three Months Ended

Nine Months Ended

 

September 30, 

September 30, 

    

2023

    

2022

    

2023

    

2022

 

Average volatility

 

40.2

%  

42.7

%  

41.4

%

41.0

%

Average risk-free interest rate

 

4.4

%  

2.9

%  

4.1

%

2.3

%

Weighted-average expected life in years

 

6.3

6.3

6.2

6.1

Dividend yield rate

 

%  

%  

%

%

Schedule of the summary of option activity under all plans

Weighted-Average

 

Weighted-Average

Remaining

Aggregate

 

Exercise

Contractual

Intrinsic

 

Options

Price

Term (Years)

Value(1)

 

(in thousands)

 

Outstanding as of December 31, 2022

7,929,150

$

17.66

 

    

    

    

Options granted

 

759,820

35.84

Options exercised

 

(786,891)

15.27

Options forfeited

 

(4,526)

29.60

Options expired

 

(543)

16.25

Outstanding as of September 30, 2023

 

7,897,010

$

19.65

4.78

208,046

Exercisable as of September 30, 2023

 

5,819,517

$

16.54

3.52

171,365

Vested and expected to vest as of September 30, 2023

7,703,355

$

19.37

4.68

205,029

(1)The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the estimated fair value of the Company’s stock for those awards that have an exercise price below the estimated fair value at September 30, 2023.
Schedule of information relating to options grants

Three Months Ended

Nine Months Ended

 

September 30, 

September 30, 

    

2023

    

2022

    

2023

    

2022

 

(in thousands, except per share data)

 

Weighted-average grant date fair value per share

$

21.49

$

14.40

$

16.76

$

14.75

Intrinsic value of options exercised

 

5,628

 

1,421

 

24,544

 

20,131

Cash received from options exercised

 

2,277

 

1,483

 

12,015

 

18,402

Total fair value of the options vested during the period

 

167

 

167

 

8,887

 

8,157

Schedule of the summary of nonvested options status

    

    

Weighted-Average

 

Grant Date

 

Options

Fair Value

 

Non-vested as of December 31, 2022

2,378,453

$

9.48

Options granted

 

759,820

16.76

Options vested

 

(1,056,254)

8.41

Options forfeited

 

(4,526)

13.40

Non-vested as of September 30, 2023

 

2,077,493

 

12.68

Schedule of information relating to RSU grants and deliveries

Total Fair Market

 

Total RSUs

Value of RSUs

 

    

Issued

    

Issued(1)

 

(in thousands)

 

RSUs outstanding at December 31, 2022

 

1,007,052

RSUs granted

 

356,176

$

12,725

RSUs forfeited

 

(2,017)

RSUs vested(2)

 

(440,337)

RSUs outstanding at September 30, 2023

 

920,874

(1)The total fair market value is derived from the number of RSUs granted times the current stock price on the date of grant.
(2)Of the vested RSUs, 168,007 shares of common stock were surrendered to fulfill tax withholding obligations.
Schedule of recorded share-based compensation expense under all plans

Three Months Ended

Nine Months Ended

 

September 30, 

September 30, 

2023

2022

2023

 

2022

 

(in thousands)

 

Cost of revenues

    

$

1,004

    

$

915

    

$

3,868

    

$

3,238

Operating expenses:

Selling, distribution, and marketing

 

213

 

178

 

649

 

540

General and administrative

 

2,975

 

2,810

 

9,323

 

8,389

Research and development

 

452

 

396

 

1,780

 

1,389

Total share-based compensation

$

4,644

$

4,299

$

15,620

$

13,556